LDC Beteiligungen UG (Lead Discovery Center)
LDC Beteiligungen UG (Lead Discovery Center) is a Dortmund, Germany-based drug development services provider founded in 2008, employing 51-100 staff, with its only documented strategic action being the 2014 acquisition of Affectis Pharmaceuticals.
- Company typePrivate
- Founded2008
- HeadquartersDortmund, Germany
- Headcount51–100
- GTM typeB2B
- OfferingServices
LDC Beteiligungen UG (Lead Discovery Center) firmographics
Firmographics- Name
- LDC Beteiligungen UG (Lead Discovery Center)
- Legal name
- LDC Beteiligungen UG (Lead Discovery Center)
- Website
- https://lead-discovery.de
- Company type
- Private
- Founded year
- 2008
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- LDC Beteiligungen UG (Lead Discovery Center) is a Dortmund, Germany-based drug development services provider founded in 2008, employing 51-100 staff, with its only documented strategic action being the 2014 acquisition of Affectis Pharmaceuticals.
- Ownership category
- akta.pro rank
LDC Beteiligungen UG (Lead Discovery Center) industry classification
Industry- Product category
- Pharmaceutical R&D Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)
- akta.pro secondary industries
- GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL), Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)
Keywords
Where LDC Beteiligungen UG (Lead Discovery Center) is headquartered
LocationHeadquarters
- HQ city
- Dortmund
- HQ country
- Germany
- HQ region
- Europe
Markets served
LDC Beteiligungen UG (Lead Discovery Center) business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations
LDC Beteiligungen UG (Lead Discovery Center) product offering
Product offeringCore offering
LDC Beteiligungen UG (Lead Discovery Center) provides drug development services to pharmaceutical and biotechnology clients. Founded in 2008 and headquartered in Dortmund, Germany, the company employs 51-100 staff engaged in lead discovery and pharmaceutical research activities. In 2014, the company expanded its capabilities through the acquisition of Affectis Pharmaceuticals.
Differentiator
Problem solved
Functional benefit
Products and services
- Drug Development Services
Companies that use LDC Beteiligungen UG (Lead Discovery Center)
Customer profileIdeal customer profiles1 record
LDC Beteiligungen UG (Lead Discovery Center) technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
LDC Beteiligungen UG (Lead Discovery Center) competitors and assessment
Company assessmentDirect peers
- Domainex: UK-based CRO offering integrated drug discovery services including medicinal chemistry, biology, and ADME. Comparable mid-sized European peer serving pharma/biotech clients with similar service models.
- Pharmaron: China-headquartered CRO providing integrated drug discovery and development services across chemistry, biology, and DMPK. Direct competitor for outsourced discovery work comparable to LDC's offerings.
- Selvita: Polish CRO offering drug discovery, medicinal chemistry, and biology services to pharma clients. Similar mid-sized European discovery services peer with comparable scale and customer base.
- Sygnature Discovery: UK-based drug discovery CRO offering medicinal chemistry, in vitro biology, and DMPK services. Comparable to LDC as a focused, mid-sized European discovery services provider.
- Evotec: German-headquartered drug discovery and development services company offering target identification, hit-to-lead, and integrated discovery platforms. Closely comparable to LDC as a fellow German discovery CRO with similar therapeutic-area focus.
Broad incumbents
- WuXi AppTec: Global CRO/CDMO offering end-to-end discovery, preclinical, and manufacturing services. A larger, broader incumbent that competes for the same pharma outsourcing dollars as LDC, particularly in small-molecule discovery.
- Charles River Laboratories: Large publicly traded CRO with extensive drug discovery and preclinical service offerings. Operates in the same customer segment (pharma/biotech R&D outsourcing) at significantly greater scale than LDC.
- Eurofins Discovery: Division of Eurofins Scientific offering drug discovery services including pharmacology, ADME, and medicinal chemistry. A broader incumbent competing in the same discovery services category as LDC.
- Merck KGaA Life Science Services: German-headquartered science and technology company with life science services and biopharma development offerings. Operates in the same domestic German market and adjacent service categories as LDC.
Regional players
- Nuvisan Pharma Services: Germany-based CRO providing drug discovery, development, and manufacturing services. Regional European peer with similar service portfolio and customer base to LDC.
Market position
Customer concentration
LDC Beteiligungen UG (Lead Discovery Center) social profiles
Digital presenceLDC Beteiligungen UG (Lead Discovery Center) financial estimates
Financial estimateRevenue estimate
Valuation estimate
LDC Beteiligungen UG (Lead Discovery Center) leadership team
Management profileNumber of profiles
LDC Beteiligungen UG (Lead Discovery Center) funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
LDC Beteiligungen UG (Lead Discovery Center) M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about LDC Beteiligungen UG (Lead Discovery Center)
What does LDC Beteiligungen UG (Lead Discovery Center) do?
LDC Beteiligungen UG (Lead Discovery Center) provides drug development services to pharmaceutical and biotechnology clients. Founded in 2008 and headquartered in Dortmund, Germany, the company employs 51-100 staff engaged in lead discovery and pharmaceutical research activities. In 2014, the company expanded its capabilities through the acquisition of Affectis Pharmaceuticals.
Is LDC Beteiligungen UG (Lead Discovery Center) a public or private company?
LDC Beteiligungen UG (Lead Discovery Center) is a private company. It is classified as unknown and is currently operating.
When was LDC Beteiligungen UG (Lead Discovery Center) founded?
LDC Beteiligungen UG (Lead Discovery Center) was founded in 2008. It employs 51 to 100 people.
Where is LDC Beteiligungen UG (Lead Discovery Center) based?
LDC Beteiligungen UG (Lead Discovery Center) is headquartered in Dortmund, Germany, in the Europe region.
Who are LDC Beteiligungen UG (Lead Discovery Center)'s main competitors?
Direct peers on record are Domainex, Pharmaron, Selvita, Sygnature Discovery and Evotec. Broad incumbents are WuXi AppTec, Charles River Laboratories, Eurofins Discovery and Merck KGaA Life Science Services. Nuvisan Pharma Services is listed as a regional player.
Does LDC Beteiligungen UG (Lead Discovery Center) have an API?
No public API is recorded for LDC Beteiligungen UG (Lead Discovery Center).
What industry is LDC Beteiligungen UG (Lead Discovery Center) in?
LDC Beteiligungen UG (Lead Discovery Center)'s product category is Pharmaceutical R&D Services. Its primary akta.pro industry code is HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery), with a secondary code of HLAGAHAL, GMP Scale-Up, Tech Transfer & Process Validation (PPQ). Its NAICS code is 541714 and its SIC code is 8731.